📰 Julia Rotow News
Julia Rotow News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Julia Rotow. Real-time updates on events, politics, business and more.
May 1, 2024
/PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically...
May 1, 2024
Trend towards better response rate, PFS compared with approved KRAS inhibitors
April 30, 2024
Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.
November 13, 2023
Ongoing research evaluating combination therapies for the frontline treatment of patients with EGFR-mutated non–small cell lung cancer could help improve survival outcomes for this patient population.
October 27, 2023
Julia Rotow, MD, discusses results from a first-in-human phase 1 study of the EGFR-targeting, BCL-XL–inhibiting antibody-drug conjugate ABBV-637 in combination with osimertinib in patients with relapsed/refractory, EGFR-mutated non–small cell lung cancer.